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Trp229 is part of the nonnucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket of HIV-1 reverse transcriptase
(RT). It is also an important constituent of the so-called “primer grip.” Using a recombinant virus assay, we tried to obtain
recombinant virus containing a Trp229Phe or a Trp229Tyr mutation in its RT. Previous studies already established the very
low DNA polymerase activities of both the Trp229Phe and the Trp229Tyr mutant RT enzymes. We were able to obtain a
Trp229Tyr but not a Trp229Phe mutant virus. However, in addition to the Trp229Tyr mutation this mutant virus also contained
an Ile63Met, a Val189Ile, and a Glu396Gly mutation in its RT. When we evaluated the quadruple mutant virus for sensitivity/
resistance against a variety of NNRTIs, no significant difference with the sensitivity/resistance profile of the single Trp229Tyr
mutant RT enzyme could be observed. We found that the three additional mutations partly restored the low RNA- and
DNA-dependent DNA polymerase activities of the Trp229Tyr mutant enzyme. Kinetic analysis revealed that both template/
primer binding and dNTP incorporation are affected by the Trp229Tyr mutation. Our findings demonstrate that a mutation at
position 229 is unlikely to occur under NNRTI drug pressure due to the poor catalytic activity of the singly mutated RT and
the favorable drug sensitivity profile of the mutated enzyme/viruses in both the absence and the presence of the
compensatory mutations. Therefore, amino acid position 229 may be regarded as an excellent amino acid target within the
NNRTI pocket for rational drug design. © 2001 Academic Presst
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Amino acid Trp229 in human immunodeficiency virus
type 1 (HIV-1) reverse transcriptase (RT) is part of the
primer grip (residues Phe227–His235) which maintains
the primer terminus in the appropriate orientation for the
nucleophilic attack on the incoming dNTP. Several inves-
tigators have studied Trp229 with regard to its role in the
primer grip (Ghosh et al., 1996, 1997; Jacques et al., 1994;
Palaniappan et al., 1997; Powell et al., 1997; Wo¨hrl et al.,
997). Residue Trp229 is not only an important constitu-
nt of the primer grip region and highly conserved
mong all known lentiviruses, it is also part of the non-
ucleoside RT inhibitor (NNRTI)-binding pocket. Indeed,
close interaction between the functional group of Tryp-
ophane 229 and the alkenyl ether part of the thiocar-
oxanilide NNRTI UC-781 has been identified in crystal
omplexes between HIV-1 RT and UC-781 (Ren et al.,
998). However, the Trp229 of HIV-1 RT has never been
eported as an NNRTI characteristic resistance mutation
ite and this can be due to the fact that replacement of
1 To whom correspondence and reprint requests should be ad-
ressed at Rega Institute for Medical Research, Minderbroedersstraat
0, B-3000 Leuven, Belgium. Fax: (32)-16-337340.143he Tryp229 by other amino acids, including the closely
elated Tyr and Phe, resulted in markedly diminished
nzyme activity. Indeed, in a recent study, we demon-
trated that mutating amino acid Trp229 to Cys, Gln, Lys,
is, Ile, Phe, or Tyr afforded in mutant RTs with severely
ompromised RNA- and DNA-dependent DNA polymer-
se activities (;3% of wild-type activity) (Pelemans et al.,
000). We also showed that the mutant RT enzymes that
ontained the Trp229Phe and Trp229Tyr mutations kept
ronounced sensitivity to the inhibitory effects of a vari-
ty of NNRTIs.
In this study, we show that although the RNA- and
NA-dependent DNA polymerase activities of Trp229Tyr-
utated RT are very low (1.1 and 3.1% of wild-type activity,
espectively), we were able to produce infectious HIV-1
hrough recombinant virus technology containing the
rp229Tyr mutation in the RT. However, three additional
utations were found in the RT coding region of the pol
ene of such mutant virus strain: Ile63Met, Val189Ile, and
lu396Gly. We demonstrated that these mutations rep-
esent compensatory mutations to increase the fitness
nd replication competence of the mutant virus and that
hey do not significantly change the resistance profile of
he mutant recombinant virus.0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
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144 PELEMANS ET AL.RESULTS
nhibitory activities of NNRTIs and dGTP against wild-
ype and Trp229Tyr mutant recombinant HIV-1 RTs
In a previous study, we showed that Trp229Tyr RT was
mong the 229-mutated enzymes that displayed the high-
st catalytic activity (Pelemans et al., 2000). Therefore, wild-
ype RT and mutant Trp229Tyr RT were evaluated for their
ensitivities to the inhibitory activities of a variety of NNRTIs
nd ddGTP (Table 1). The 229Tyr mutated HIV-1 RT showed
catalytic activity that was approximately #2% of that of
ild-type enzyme. The mutant Trp229Tyr RT showed mar-
inal resistance to delavirdine (2.4-fold), nevirapine (2.7-
old), and quinoxaline GW420867X (fivefold). A more sub-
tantial resistance was noted for emivirine (8.5-fold), and,
articularly, the decreased inhibitory effect of the thiocar-
oxanilide UC-781 was substantial (21-fold). Quinoxaline
BY 097, efavirenz, and ddGTP retained full inhibitory ac-
ivity against the Trp229Tyr-mutated RT.
eneration of recombinant HIV-1 strains mutated at
mino acid position 229
Since Trp229Phe and Trp229Tyr RT showed a better
atalytic activity than HIV-1 RTs that contained other
mino acids at position 229, we attempted to construct
ecombinant viruses with the Trp229Phe or Trp229Tyr
utation in the pol gene. Under the experimental condi-
ions used, wild-type recombinant virus was easily gen-
rated. However, three independent attempts to gener-
te Trp229Phe or Trp229Tyr RT recombinant viruses
ailed to recover viable mutant virus strains except in one
ase. In all other cases, there was no sign of virus
reakthrough, either microscopically (cytopathogenicity)
r by p24 measurement. The recombinant virus strain
hat emerged approximately 1 month after the initiation of
TABLE 1
Sensitivity of HIV-1 Wild-Type RT to the Inhibitory Effects
of NNRTIs and ddGTP
IC50 (mM)
a
NNRTI Wild-type Trp229Tyr
Nevirapine 6.2 6 0.3 16.7 6 0.3
elavirdine 0.66 6 0.04 1.6 6 0.9
favirenz 0.02 6 0.01 0.02 6 0.00
mivirine 0.122 6 0.007 1.03 6 0.09
HBY 097 0.014 6 0.002 0.020 6 0.006
GW 420867X 0.04 6 0.02 0.19 6 0.09
UC-781 0.022 6 0.001 0.5 6 0.4
ddGTP 0.42 6 0.04 0.6 6 0.1
a IC50, or 50% inhibitory concentration required to inhibit the enzyme
activity by 50%, using poly(rC) z oligo(dG12–18) as the template-primer and
[2,8-3H]dGTP as the radiolabeled substrate.ne of the experiments contained the Trp229Tyr mutationn the presence of two additional amino acid changes
Ile63Met and Val189Ile). Initially, we were unsuccessful
n cultivating the recombinant virus again in CEM or MT4
ell cultures. Only after subcultivating the recombinant
irus for a prolonged period of time (three passages) on
T4 cells did mutant virus emerge in the cell culture.
hen the RT gene of this virus was sequenced, a third
utation at amino acid position 396 (Glu396Gly) was
ound to be added to the Trp229Tyr/Ile63Met/Val189Ile
enetic background.
ensitivitiy of the Ile63Met/Val189Ile/Trp229Tyr/
lu396Gly quadruple mutant recombinant virus
o NNRTIs
A set of representative NNRTIs was used to deter-
ine the resistance profile of the Trp229Tyr/Ile63Met/
al189Ile/Glu396Gly recombinant virus to NNRTIs and
dG (Table 2). The highest degree of drug resistance
as noted for nevirapine (;23-fold), followed by the
uinoxalines GW 420867X and HBY 097 (approximately
ive- to eightfold) and emivirine (approximately seven-
old). Marginal resistance was observed for UC-781 (2.5-
old) and delavirdine (2.5-fold). The Trp229Tyr/Ile63Met/
al189Ile/Glu396Gly recombinant virus kept full sensitiv-
ty to efavirenz (Table 2). Thus, the Tryp229 may be
onsidered a good target for rational drug design since
or the majority of NNRTIs pronounced antiviral activity
as preserved against the Trp229Tyr RT mutated enzymes.
atalytic activity of the Trp229Tyr, Trp229Tyr/
le63Met/Val189Ile, and Trp229Tyr/Ile63Met/
al189Ile/Glu396Gly mutant recombinant RTs
The additional mutations found in the RT gene of the
ecovered Trp229Tyr RT mutant recombinant virus (i.e.,
le63Met, Val189Ile, and Glu396Gly) were introduced by
ite-directed mutagenesis into the Trp229Tyr RT genetic
TABLE 2
Sensitivity of the Ile63Met/Val189Ile/Trp229Tyr/Glu396Gly Mutant
Recombinant Virus to NNRTIs
Compounds
EC50 (mM)
a
Wild-type
Trp229Tyr/Ile63Met/
Val189Ile/Glu396Gly
Nevirapine 0.012 6 0.004 0.30 6 0.1
Delavirdine 0.03 6 0.01 0.07 6 0.04
Efavirenz 0.0013 6 0.0002 0.001 6 0.000
Emivirine 0.0046 6 0.0007 0.03 6 0.01
HBY 097 0.0011 6 0.0003 0.006 6 0.001
W 420867X 0.004 6 0.002 0.034 6 0.006
C-781 0.0015 6 0.0001 0.004 6 0.002
dG 2.6 6 1.7 0.7 6 0.2
a EC50, 50% effective concentration or compound concentration required
to inhibit HIV-1 induced cytopathicity in CEM cell cultures by 50%.
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145MUTATIONS OF HIV-1 RT RESTORE DNA POLYMERASE ACTIVITYbackground. The purified triple Trp229Tyr/Ile63Met/
Val189Ile and quadruple Trp229Tyr/Ile63Met/Val189Ile/
Glu396Gly mutant RT enzymes were assayed for RNA-
and DNA-dependent DNA polymerase and RNase H ac-
tivities (Fig. 1). The analysis of the RNA-dependent DNA
polymerase (RdDp) and DNA-dependent DNA polymer-
ase (DdDp) activities revealed severely impaired enzy-
matic functions for all the mutated enzymes compared to
wild-type RT (Fig. 1). Nevertheless, small but noticeable
increases in both RdDp and DdDp activities were ob-
served when additional amino acid mutations were
added to the Trp229Tyr RT genetic background. The
extra mutations at amino acid positions 63 (Ile63Met) 1
189 (Val189Ile) raised the RdDp activity from 1.6 to 2.7%
and the DdDp activity from 3.6 to 5.7% of wild-type RT
activity for Trp229Tyr RT and Trp229Tyr/Ile63Met/
Val189Ile, respectively (Fig. 1). Moreover, adding the
Glu396Gly mutation to the Trp229Tyr/Ile63Met/Val189Ile
genetic background eventually further increased the
RdDp activity to 5.1% and the DdDp activity to 8.5%. Thus,
overall, the RdDp activity of the quadruple RT mutant was
raised by a factor of 3.1 and the DdDp activity by a factor
of 2.3, as compared to the enzymatic activities of the
single mutant Trp229Tyr RT (Fig. 1). The RdDP activity of
the mutant enzymes was also determined using a primed
Escherichia coli 16S–23S heteropolymeric ribosomal
RNA template as described previously (Balzarini et al.,
1992). The mutant enzymes showed again severely im-
paired DNA polymerizing activities that were for the sin-
gle, triple, and quadruple mutant enzymes below 10% of
those recorded for wild-type enzyme. In (sharp) contrast
with the severely reduced RNA and DNA-dependent
FIG. 1. RdDp, DdDp, and RNase H activities of Trp229Tyr, Trp229
ecombinant HIV-1 RTs. Wild-type activities are designated as 100%.DNA polymerase activities, the RNase H activities of theTrp229Tyr, the Trp229Tyr/Ile63Met/Val189Ile, and the
Trp229Tyr/Ile63Met/Val189Ile/Glu396Gly mutant recom-
binant RTs were comparable with the RNase H activity of
wild-type RT when assessed in standard assays using
homopolymeric RNA/DNA duplex substrates (Fig. 1). In
addition, no differences were observed in the types and
extents of cleavage of the RNA in a heteropolymeric
RNA/DNA substrate (Fig. 2).
Kinetic analysis of the Trp229Tyr, Trp229Tyr/Ile63Met/
Val189Ile, and Trp229Tyr/Ile63Met/Val189Ile/Glu396Gly
mutant recombinant RTs
Kinetic analysis was performed with both the substrate
(i.e., dGTP) and template/primer (i.e., poly(rC) z oligo(dG)) as
the variable parameters. The kinetic parameters for the
different mutant RTs with dGTP as the variable substrate
are summarized in Table 3. The Km of wild-type RT and
Trp229Tyr RT for dGTP were 3.7 and 184 mM, respectively.
The higher Km of the Trp229Tyr mutant for dGTP indicates
hat this mutant has a markedly lower affinity for dGTP
inding compared to wild-type RT. In addition, the kcat of the
Trp229Tyr mutant was substantially lower (;13-fold) than
the kcat of wild-type RT, indicating that the Trp229Tyr mutant
RT allows fewer substrate molecule incorporations per unit
time than wild-type RT. The higher Km combined with the
lower kcat results in a catalytic efficiency (kcat/Km) that is only
0.16% of the catalytic efficiency of wild-type RT (Table 3).
Addition of the Ile63Met and Val189Ile mutations low-
ered the Km by a factor of 2 compared to the Trp229Tyr
utant. The kcat was also slightly increased, yielding a
threefold increase in catalytic efficiency compared to the
63Met/Val189Ile, and Trp229Tyr/Ile63Met/Val189Ile/Glu396Gly mutantTyr/IleTrp229Tyr mutant (Table 3). Among the mutant RTs, the
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146 PELEMANS ET AL.quadruple Ile63Met/Val189Ile/Trp229Tyr/Glu396Gly mu-
tant enzyme possessed the lowest and thus closest Km
value to wild-type RT (Table 3). Its kcat was slightly higher
than the kcat of the triple mutant, resulting in a catalytic
fficiency that was somewhat higher (;1.5-fold) than that
f the triple enzyme mutant.
The kinetic parameters for the different mutant RTs
ith poly(rC) z oligo(dG) as the variable template/primer
re summarized in Table 4. Wild-type RT has a Km for
FIG. 2. Autoradiography of wild-type and mutant RNase H-generated
degradation products as described under Materials and Methods.
TABLE 3
Kinetic Analysis with dGTP as the Variable Substrate
Enzyme K m
a k cat
b k cat/K m
Wild-type 3.7 6 0.2 0.075 6 0.006 0.02
Trp229Tyr 184 6 11 0.0058 6 0.0002 0.00003
Trp229Tyr/Ile63Met/
Val189Ile 84 6 5 0.0079 6 0.0018 0.00009
Trp229Tyr/Ile63Met/
Val189Ile/Glu396Gly 54 6 2 0.0084 6 0.0002 0.00016
Note. The data are means of three independent experiments
(means 6 standard deviations).
a K m is in mM.
b 21k cat is in s .oly(rC) z oligo(dG) of 5.4 mM. The Km of the Trp229Tyr
utant was five times higher, i.e., 28 mM (Table 4). The
cat of the Trp229Tyr mutant was 100 times lower than
that of wild-type RT. This might indicate that the bound
template/primer was not in a good position for efficient
catalysis. The addition of the Ile63Met and Val189Ile
mutations to Trp229Tyr RT only slightly improved the
affinity of the Trp229Tyr RT for the template/primer but
increased the kcat by a factor of 2.4 relative to Trp229Tyr
RT. As a result, the catalytic efficiency was raised by a
factor of ;3 (Table 4). In contrast, the quadruple
Glu396Gly mutant enzyme had a decreased Km (;3.5-
fold) and increased kcat (;1.6-fold), yielding a catalytic
efficiency that was 15-fold higher than that of the
Trp229Tyr single RT mutant.
DISCUSSION
In a previous study, we focused on Trp229 as a poten-
tial candidate amino acid for targeted drug design of
NNRTIs. We studied the effect of a variety of rationally
chosen mutations at position 229 both on the catalytic
activity of the mutant enzymes and on their associated
sensitivity/resistance profile to NNRTIs. All of the 229-
mutated recombinant RT enzymes showed severely
compromised-to-undetectable DNA polymerase activi-
ties (Pelemans et al., 2000). The Trp229Tyr recombinant
T enzyme, which was among the mutant enzymes with
he highest catalytic activity, was evaluated for sensitivity
gainst several NNRTIs (Pelemans et al., 2000) and
howed little, if any, resistance against most of the NNR-
Is (Table 1).
Several investigators reported that they were unable to
roduce infectious HIV-1 containing a Trp229Ala muta-
ion (Jacques et al., 1994, Ghosh et al., 1996). We also
ttempted to make recombinant virus bearing either the
rp229Phe or the Trp229Tyr mutation several times be-
ore we eventually succeeded in making a Trp229Tyr-
utated recombinant virus. However, careful analysis of
TABLE 4
Kinetic Analysis with Poly(rC) z Oligo(dG)a as the Variable
Template/Primer
Enzyme K m
b k cat
c k cat/K m
Wild-type 5.4 6 0.4 0.18 6 0.05 0.033
Trp229Tyr 28 6 20 0.0017 6 0.0003 0.00006
Trp229Tyr/Ile63Met/
Val189Ile 24 6 19 0.0042 6 0.0007 0.00018
Trp229Tyr/Ile63Met/
Val189Ile/Glu396Gly 7.4 6 1.9 0.0067 6 0.0006 0.0009
Note. The data are means of three independent experiments
(means 6 standard deviations).
a dGTP: 1 mCi.
b K m is in mM.
c 21k cat is in s .
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147MUTATIONS OF HIV-1 RT RESTORE DNA POLYMERASE ACTIVITYthe amino acid sequence of the RT gene revealed that
the mutant Trp229Tyr RT HIV-1 strain that eventually
emerged after a prolonged incubation time contained
three additional amino acid mutations, namely Ile63Met,
Val189Ile, and Glu396Gly. We found that these additional
mutations did not change the drug sensitivity/resistance
profile of the mutant virus, as compared to the drug
sensitivity/resistance profile of the singly mutated
Trp229Tyr RT (compare data in Tables 3 and 4), but rather
represent compensatory mutations that might have
served to increase the fitness and replication compe-
tence of the mutant virus. From the kinetic analyses with
dGTP and poly(rC) z oligo(dG), it was evident that the
Trp229Tyr mutation seriously affected both template/
primer binding and dNTP incorporation. Similar observa-
tions were made by Wo¨hrl et al. (1997) for the Trp229Ala
RT mutant. Although the addition of the Ile63Met,
Val189Ile, and Glu396Gly mutations to the Trp229Tyr-
mutated RT background systematically improved the Km
and/or kcat of the mutant enzymes, resulting in increased
catalytic efficiencies, the overall catalytic efficiency of the
quadruple mutant remained still significantly lower than
that of wild-type RT. In fact, only the Km for template/
primer was improved to almost wild-type levels upon
addition of the extra mutations. Interestingly, in contrast
with the severely reduced RNA- and DNA-dependent
activities, the RNase H activity of the single Trp229Tyr,
triple Ile63Met/Val189Ile/Trp229Tyr, and quadruple
Ile63Met/Val189Ile/Trp229Tyr/Glu396Gly mutant recom-
binant RTs was unaffected. Surprisingly, the correspond-
ing recombinant (quadruple) mutant virus was capable of
efficient replication in CEM and MT4 cell cultures. It is
therefore tempting to suggest a threshold of ;5% resid-
ual DNA polymerase activity for the virus to replicate
efficiently in cell culture. However, it should be kept in
mind that the overall polymerase activity measurements
do not take into account specific events such as initiation
of DNA synthesis from the tRNALys,3 primer during (2)-
trand DNA synthesis and the generation and extension
f the PPT (polypurine tract) primer during (1)-strand
NA synthesis. These latter events are essential steps in
he reverse transcription process and have been shown
o be impaired for the singly mutated Trp229Phe and
rp229Tyr mutant RTs (Ghosh et al., 1997).
The appearance of compensatory mutations has also
een reported for Gly190Glu RT mutant virus, which has
een shown to emerge in the presence of quinoxalines
Kleim et al., 1996). This virus contains an RT that dis-
lays only ;5% of the catalytic activity of wild-type RT. On
rolonged exposure of this mutant virus to quinoxaline,
dditional mutations (i.e., Leu74Val and Val75Thr) ap-
eared that did not further enhance the level of drug
esistance, but that markedly increased the catalytic ef-
icacy of the enzyme and concomitant fitness of the virus
Boyer et al., 1998; Kleim et al., 1996). Recently, Olivareset al. (1999) reported on the appearance of a mutation atamino acid position 230 (i.e., Met230Ile) within the primer
grip, which compensated for the dNTP binding defect
caused by a Tyr115Trp mutation and the resulting poor
replicative capacity of the Tyr115Trp recombinant mutant
virus. Thus, the additional mutations that appeared in the
Trp229Tyr RT mutant virus should also be considered as
compensatory mutations to increase the catalytic efficiency
of the mutant enzyme, and thus, the fitness of the corre-
sponding virus, but not—as shown in this study—to further
increase drug resistance of the enzyme or virus.
In an attempt to rationalize our observations, the crys-
tallographic structure for a stalled HIV-1 RT transcription
complex (Huang et al., 1998) was examined. Uniquely,
this structure (PDB code 1RTD) offers insight into the
extremely complicated interplay of interactions between
the enzyme, the incoming dNTP, the template strand, and
the nascent primer strand. The interactions relevant to
this study are summarized schematically in Fig. 3A. Res-
FIG. 3. Structural context for the role of several amino acid mutations.
(A) A schematic representation of interactions between wild-type HIV-1 RT
residues 63, 189, 229, and 396 and the extending primer-template during
transcription. (B) A ball-and-stick representation of the catalytic site of the
complex to highlight potential roles for the mode of action of the Val189Ile
compensation mutation. Figure 2B was created using BobScript (Esnouf,
1999).idue 229 has mainly a structural role in the p66 palm
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148 PELEMANS ET AL.domain. On one side it interacts with the side chain of
Met230, which, in turn, is crucial for positioning the
ribose ring of the 22 nucleoside in the extending primer
strand (Fig. 3B). On the other side, residue 229 interacts
with Tyr188, which is part of the b-sheet containing the
catalytic aspartic acid residues 110, 185, and 186. The
side chain of residue 189 lies on the opposite side of the
b-sheet to that of Tyr188. The Val189Ile mutation in-
creases the bulk of this residue and may thus force
Tyr188, and hence residues 229 and 230, slightly toward
the primer strand. In this way, an enlargement of residue
189 may partly compensate for the decrease in size of
the side chain for the Trp229Tyr mutation. An alternative
hypothesis is that an enlargement of residue 189 may
adjust the position of the b-sheet containing the catalytic
spartic acid residues, hence altering the geometry of
he catalytic site itself in some compensatory way. The
ide chain of residue 63 sits in the gap between the
emplate base in the catalytic site (template nucleoside
) and the next one to be transcribed (template nucleo-
ide 11). The Ile63Met mutation probably causes a fairly
inor change, but a small repositioning of the template
ase in the catalytic site may help compensate for a
arger change in position of the primer strand caused by
he Trp229Tyr mutation. Finally, the Glu396Gly mutation
robably exerts its effect through the p51 subunit rather
han through the p66 subunit, where it is positioned far
rom the template-primer groove. In the p51 subunit,
owever, residue 396 is located in the putative “RNase H
rimer grip,” a region that was recently proposed to
ake significant contacts with the RNA/DNA duplex sub-
trate (Sarafianos et al., 2001). Residue 396 hydrogen
onds with the nearby positively charged side chains of
rg358 and Lys422 (both in the p66 subunit) (Fig. 3).
hese side chains form part of the positively charged
inding groove, interacting with the phosphate backbone
f primer nucleoside 210. A loss of the hydrogen bond-
ng potential of residue 396 may thus alter the course of
he positively charged groove in such a way that it partly
ompensates for the Trp229Tyr mutation, although such
compensation would be occurring over a very long
ange. The lack of effect of the Glu396Gly substitution
uggests either that residue 396 does not play an impor-
ant role in contacting the nucleic acid substrate, or more
ikely, that the protein–nucleic acid contacts are so ex-
ensive that a single substitution has little net effect on
nzyme activity in the assay systems employed.
In conclusion, although the Trp229Tyr mutation results
n an RT enzyme with extremely low DNA polymerase
ctivities, we were able to recover recombinant virus
arrying a Trp229Tyr mutation. Three additional muta-
ions, Ile63Met, Val189Ile, and Glu396Gly, were found
hat restored part of the low DNA polymerase activities of
he Trp229Tyr mutant preserving a high sensitivity profile
f the Trp229Tyr mutant to a variety of NNRTIs. Together,
ur data demonstrate that a mutation at position 229 is wnlikely to occur under NNRTI drug pressure due to the
oor catalytic activity of the singly mutated RT and the
avorable drug-sensitivity profile of the mutated enzyme/
iruses in the presence of the compensatory mutations.
herefore, amino acid position 229 may be regarded as
n excellent amino acid target within the NNRTI pocket
or rational drug design.
MATERIALS AND METHODS
est compounds
The thiocarboxanilide UC-781 (N-[4-chloro-3-(3-methyl-2-
utenyloxy)phenyl]-2-methyl-3-furan-carbothioamide) was
btained from Uniroyal Chemical Ltd. (Middlebury, CT, and
uelph, ON, Canada). Nevirapine (dipyridodiazepinone; BI-
G-587) was kindly provided by Dr. P. Ganong (Boehringer
ngelheim, Ridgefield, CT). Delavirdine (BHAP, [bis(het-
roaryl)piperazine] U-90152), quinoxaline HBY 097 [(S)-4-
sopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-
ihydroquinoxaline-2(1H)-thione], and efavirenz (DMP 266)
ere kindly provided by Dr. R. Kirsch (Hoechst AG, Frank-
urt, Germany). Emivirine (MKC-442), a HEPT [1-(2-hy-
roxyethoxymethyl)-6-(phenylthio)thymine] derivative was
rovided by Dr. M. Baba (Fukushima Medical College,
ukushima, Japan) and Dr. P. Furman (Triangle Pharmaceu-
icals, NC). GW420867X was kindly provided by Dr. J.-P.
leim (Glaxo Wellcome, Stevenage, UK). 29,39-Dideoxy-
uanosine (ddG) was from Sigma Chemical Ltd. (St. Louis,
O).
ells
CEM cells were obtained from the American Type
ulture Collection (Rockville, MD). MT4 cells were pro-
ided by Dr. N. Yamamoto (Tokyo Medical School and
ental University School of Medicine, Tokyo, Japan).
ctivity assay for the NNRTIs against wild-type and
utant recombinant HIV-1 in CEM cell cultures
CEM cells were suspended at approximately 250,000
ells per milliliter of culture medium and infected with
ild-type HIV-1(IIIB) at approximately 100 times the 50%
ell culture infective dose (CCID50) per milliliter. Then,
00 ml of the infected cell suspensions were added to
200-ml microtiter plate wells containing 100 ml of an
appropriate dilution of the test compounds. After 4 days
incubation at 37°C, the cell cultures were microscopi-
cally examined for syncytium formation. The EC50 (50%
ffective concentration) was determined as the com-
ound concentration required to inhibit syncytium forma-
ion by 50%.
ite-directed mutagenesis of HIV-1 RT
Mutant RT enzymes containing the Trp229Phe,
rp229Tyr, Ile63Met, Val189Ile, and Glu396Gly mutations
ere derived from the RT sequence cloned in pKRT2His
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Site-directed mutagenesis was performed using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
Westburg, The Netherlands). The PAGE-purified oligonu-
cleotides were ordered from Amersham Pharmacia Bio-
tech (Roosendaal, The Netherlands) and are described
in Table 5. The presence of the desired mutations was
determined by restriction analysis with BstXI (Life Tech-
nologies, Merelbeke, Belgium) in the case of the 229
mutations and with BstYI (Life Technologies) in the case
of the Val189Ile mutation and confirmed by sequencing
of the RT gene on an ABI Prism 310 sequencer (Applied
Biosystems, Brussels, Belgium) using the dRhodamine
Terminator Cycle Sequencing Ready Reaction Kit (Ap-
plied Biosystems). For the Ile63Met and the Glu396Gly
mutations, it was not possible to introduce or remove a
restriction site by introducing a silent mutation in the
mutagenesis primer and therefore the presence of these
mutations was verified by sequencing of the RT gene.
Expression and purification of mutant recombinant
HIV-1 RT
Recombinant HIV-1 RT enzymes were expressed from
a two-plasmid coexpression system described by Jonck-
heere et al. (1996). The p66 subunit of RT is expressed
from pACYC66His and the p51 subunit from pKRT51. To
construct wild-type and mutated pACYC66His, wild-type
and mutated pKRT2His was digested with MstI and
EcoRI and the RT-containing fragment was ligated into
pACYC184 digested with ScaI and EcoRI. To construct
wild-type and mutated pKRT51, wild-type and mutated
pKRT2His was digested with NcoI and KpnI and the
RT-containing fragment was ligated into pKRT51 digested
with NcoI and KpnI.
Expression and purification of the recombinant RTs
was performed as described previously (Pelemans et al.,
1998).
Reverse transcriptase assay
For determination of the 50% inhibitory concentrations
(IC50) of the test compounds, the RT assay was per-
formed as described previously (Balzarini et al., 1992). A
TABLE 5
Primers Used for Site-Directed Mutagenesis of the RT Gene
Mutation Sense primer sequencea
Trp229Phe 59-GAACCTCCATTTCTTTTCATGGGTTATGAACTCCATCC-39
Trp229Tyr 59-GAACCTCCATTTCTTTACATGGGTTATGAACTCCATCC-39
Ile63Met 59-CTCCAGTATTTGCCATGAAGAAAAAAGACAG-39
Val189Ile 59-GGATGATTTGTATATAGGGTCTGACTTAGAAATAGGG-39
Glu396Gly 59-CCCATACAAAAGGGAACATGGGAAACATGGTGG-39
a The mutated codons are marked in bold. The removed BstXI (229
rimers) and BstYI (189 primer) restriction sites are underlined.fixed concentration of the radiolabeled substrate [2,8-3H]dGTP (specific radioactivity 14.1 Ci/mmol, Amersham
harmacia Biotech) (1 mCi or 1.4 mM) and a fixed con-
entration of the template-primer poly(rC) z oligo(dG12–18)
0.1 mM; Amersham Pharmacia Biotech) were used in the
eaction mixture containing a variety of drug concentra-
ions. The IC50 for each test compound was determined
as the compound concentration that inhibited recombi-
nant RT activity by 50%.
The RNA- and DNA-dependent DNA polymerase ac-
tivities of the recombinant RTs were determined in a
similar way using a fixed concentration of either
poly(rC) z oligo(dG12–18) or poly(dC) z oligo(dG12–18) (0.1 mM;
Amersham Pharmacia Biotech), respectively.
Steady-state kinetic assays were performed as de-
scribed previously (Balzarini et al., 1992), except that the
reaction mixtures were incubated for 30 min instead of
60 min during the assays with variable dGTP substrate
concentrations. Under these experimental conditions the
catalytic reaction of the different mutant enzymes pro-
ceeded linearly and proportionally with time. The Km and
kcat values for poly(rC) z oligo(dG12–18) and dGTP were de-
termined in the presence of 1.4 mM (1 mCi) [2,8-3H]dGTP
specific radioactivity 14.1 Ci/mmol) and 0.1 mM
oly(rC) z oligo(dG12–18), respectively. The Km and Vmax (kcat)
alues were derived from the double-reciprocal (Line-
eaver–Burk) plots of the concentrations of the variable
ubstrate (i.e., dGTP or poly(rC) z oligo(dG12–18)) versus the
velocities of dGTP incorporation at each concentration.
RNase H assay
Two types of assays for RNase H activity were carried
out. The first assay system assessed the release of
acid-soluble radioactivity from the substrate poly([3H]rG)-
poly(dC) and was performed essentially as described by
Borkow et al. (1997). The second assay was a gel-based
assay that used a 25 nucleotide 59 32P-heteropolymeric
RNA template (59-UGG UGG GCG CCG UCG GUG UGG
GCA A-39) annealed to the complementary 25 nucleotide
DNA oligomer (59-TTG CCC ACA CCG ACG GCG CCC
ACC A-39). The 59 [32P]RNA–DNA duplex (50 nM) was incu-
ated with 5 nM of wild-type or mutant RT heterodimer in 50
M Tris–HCl pH 7.9, 60 mM KCl, 2.5 mM MgCl2 in a final
volume of 10 mL. Samples were incubated for 10 min at
37°C and then quenched with an equal volume of gel
loading dye (98% deionized formamide, 10 mM EDTA, 1
mg/mL bromphenol blue, and 1 mg/mL xylene cyanol).
RNase H-generated degradation products were resolved
by electrophoresis using 14% acrylamide/7 M urea se-
quencing gels, visualized by autoradiography (Kodak X-
OMAT film), and quantified by densitometry.
Recombinant virus assay
The recombinant virus assay as described by Kellam
and Larder (1994) was used with minor modifications
(Vandamme et al., 1999). Briefly, recombinant viruses
were obtained through homologous recombination of the
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150 PELEMANS ET AL.desired RT gene with RT gene-deleted proviral DNA that
was propagated in pHIVDRTBstEII. The RT gene DNA
used in the recombination came from a PCR (primers IN3
and IN5) performed on the 229-mutated pACYC66His.
MT4 cells were electroporated with ;2 mg of RT gene
DNA and ;5 mg of pHIVDRTBstEII DNA. Upon success-
ul homologous recombination, viable recombinant virus
ould be recovered from the cell cultures. The nature of
he mutation at amino acid position 229 in the RT of the
utant recombinant viruses was confirmed by sequenc-
ng the complete RT gene on an ABI Prism 310 Se-
uencer (Applied Biosystems).
nalysis of the reverse transcriptase structure
The crystallographic structure of a stalled HIV-1 RT
ranscription complex (PDB code 1RTD; Huang et al.,
998) was examined using the program MidasPlus on a
ilicon Graphics Indigo2 workstation. The ball-and-stick
T model was created using BobScript (Esnouf, 1999).
o attempt was made to directly model the mutations in
he HIV-1 RT because current methodologies would have
een unable to predict subtle effects for such a large and
omplex binding site as the polymerase active site.
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